Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF3 | O95398 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6734631 | 0.93 | RAPGEF3 (0.38) | RAPGEF3HRH3SMN1; SMN2MCHR1 | |
| SCHEMBL6805174 | 0.86 | HRH3 (0.40) | RAPGEF3HRH3MCHR1 | |
| SCHEMBL6840959 | 0.82 | HRH3 (0.40) | HRH3SIGMAR1 | |
| SCHEMBL6737935 | 0.79 | RAPGEF3 (0.44) | RAPGEF3HRH3SMN1; SMN2POLBMCHR1 | |
| SCHEMBL6735891 | 0.79 | HRH3 (0.42) | HRH3SIGMAR1 | |
| SCHEMBL6729982 | 0.77 | HRH3 (0.40) | RAPGEF3HRH3MCHR1 | |
| SCHEMBL7659514 | 0.77 | RAPGEF3 (0.46) | RAPGEF3HRH3MCHR1 | |
| SCHEMBL7660195 | 0.77 | HRH3 (0.47) | RAPGEF3HRH3SIGMAR1 | |
| SCHEMBL6736042 | 0.76 | RAPGEF3 (0.43) | RAPGEF3HRH3SMN1; SMN2POLBMCHR1 | |
| SCHEMBL6730287 | 0.72 | HRH3 (0.42) | HRH3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127507-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-07-01 | — | — | US | disclosed |
| US-20040122026-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-24 | — | — | US | disclosed |
| US-20030225288-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127507-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | RAPGEF3 2984/4885HRH3 530/4885SMN1; SMN2 853/4885 |
| US-20030225288-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | RAPGEF3 2984/4885HRH3 530/4885SMN1; SMN2 853/4885 |
| US-20040122026-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | RAPGEF3 2984/4885HRH3 530/4885SMN1; SMN2 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.